成都招聘

1.在医院院长、医务科领导下负责急诊科医疗、护理、教学、科研和行政管理工作。

2.负责制定业务技术建设规划、年度工作计划和医疗护理质量监控方案并组织实施,定期检查和总结。

3.负责组织并参与急诊病员诊治、危重患者抢救、复苏与监护，适时组织院前急救。

4.组织指挥大批创伤、中毒等重大急诊病人的救治并及时向医务科和院领导报告。

5.经常检查急救药品、器材的使用、管理情况。

6.参与组织院外急救小组,指定车辆,配齐药品器材,放在固定位置,随时处于应急状态。

7.负责组织本科业务训练、人才培养和技术考核。

8.引进国内外先进技术开展新业务和科学研究，及时总结经验撰写学术论文。

9.督促本科人员认真执行各项规章制度和技术操作常规经常进行安全教育,严防事故、差错。

任职要求：

1.本科及以上学历；

2.副主任医师及以上职称；

3.5年以上三甲医院工作经历；

中健瑞杰生物科技股份有限公司正在入驻四川省自贸区天府生命科学园区内，注册资金1.亿元，以前沿医学生物技术为核心，以再生医学、特需医疗为平台。集科研、临床、产品服务三位一体的精准医疗高科技企业。
CHR Biotechnology Co., Ltd is entering the Tianfu Life Science Park in the Sichuan Free Trade Zone, with a registered capital of 100 million yuan, with cutting-edge medical biotechnology as the core, regenerative medicine and special-needed medicine as the platform. CHR is a precision medical high-tech company integrating scientific research, clinical practice, and product services.
公司致力于生物医学技术临床研究、高端生物产品服务、精准医疗、细胞存储四大业务领域。注重夯实产业基础，强化各项体系建设，秉承“科技创新为企业***生产力”理念，汇聚国内外生物医疗领域高尖端科技专家及人才，引进行业先进的实验室设备，不断加大科研投入。目前筹备自主研发多项干细胞技术临床应用实验，力争生物技术及再生医学领域达到国际领先水平。
CHR is committed to the four major business areas including biomedical technology clinical research, high-end biological product services, precision medicine, and cell storage. We focus on consolidating the industrial foundation, strengthening the construction of various systems, adhering to the concept of "Science and technology are the primary productive forces", gathering high-tech experts and talents in the biomedical field in China and abroad, introducing advanced laboratory equipment in the industry, and continuously increasing investment in scientific research. We are currently preparing to independently research and develop a number of clinical application experiments of stem cell technology, and strive to take the world's leading position in the fields of biotechnology and regenerative medicine.
公司权威生物科研专家团队、联合国家卫健委批准的知名三甲医院开展临床研究。以前沿生物医疗技术成果应用为依托。
Relying on the application of cutting-edge biomedical technology achievements, CHR authoritative biological scientific research expert team will carry out clinical research in conjunction with well-known tertiary hospitals approved by the National Health Commission.
公司未来主要业务和研究内容：
Business Scope and Research Directions
1、细胞制备技术及质控体系研发：将建立符合GLP、cGMP及cGTP标准的细胞制备技术平台，开展包括干细胞制剂及应用的标准化研究，形成一整套完备的细胞制备和质控技术体系。
1. Research and development of cell preparation technology and quality control system. A cell preparation technology platform that complies with GLP, cGMP and cGTP standards will be established, and standardized research including stem cell preparations and applications will be carried out to form a complete set of cell preparation and quality control technology systems.
2、细胞存储体系：将开发以干细胞（脐带血造血干细胞、脐带间充质干细胞、***间充质干细胞、脂肪间充质干细胞等）和免疫细胞（外周血NK、CIK、DC、Car-T等）存储为核心的生物技术平台建设，打造区域性细胞存储基地。
2. Cell storage system. A biotechnology platform concentrates on the storage of stem cells (umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose-derived mesenchymal stem cells, etc.) and immune cells (peripheral blood NK, CIK, DC, Car-T, etc.) will be developed and constructed to build a regional cell storage base.
3、细胞产品体系：将自主研发具有独立知识产权的细胞制备上下游相关产品的产供销业务，包括干细胞药物备案、美妆相关产品的商品化和市场销售等。
3. Cell product system. Independently research and develop the cell preparation production, up-and downstream supply and marketing business with independent intellectual property rights, including the filing of stem cell drugs, the commercialization and market sales of beauty-related products.
4、细胞与分子临床检验体系：将建立基于常规五大检验技术体系为基础的、以细胞与分子临床检验为特色的研究型临床检验体系。
4. Cellular and molecular clinical testing system. A research-based clinical testing system featuring cellular and molecular clinical testing based on the 5 conventional testing technology systems will be established.
5、个体化健康管理和保健服务：以健康大数据为基础、生物统计学为手段，从基因和细胞水平探求个性化精准医学、解析人体健康奥秘，建立专业化健康服务平台。
5. Individualized health management and health services. Based on health big data and biostatistics, we will explore personalized precision medicine at the genetic and cellular level, analyze the mysteries of human health, and establish a professional health service platform.
6、干细胞临床转化研究：公司着眼干细胞临床转化，聚焦缺血性脑卒中、糖尿病和骨关节炎等疾病干细胞治疗，将与四川省内外的多家三甲医院开展干细胞临床转化研究。
6. Stem cell clinical transformation research. Focusing on the clinical transformation of stem cells, as well as stem cell treatment for diseases such as ischemic stroke, diabetes and osteoarthritis, it will conduct stem cell clinical transformation research with many top three hospitals in Sichuan Province.